William Blair downgraded MiNK Therapeutics (INKT) to Market Perform from Outperform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK data published showing complete remission, says H.C. Wainwright
- Promising Clinical Results and Positive Outlook for MiNK Therapeutics’ agenT-797 Drive Buy Rating
- Mink Therapeutics Inc trading resumes
- Mink Therapeutics Inc trading halted, volatility trading pause
- Why Is MiNK Therapeutics Stock (INKT) Up 190% Today?